Differentiating COPD from asthma in clinical practice

Postgraduate Medicine

Volumn 121, Issue 3, 2009, Pages 105-112

  Mosenifar, Zab ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adrenergic beta agonists; Asthma; Chronic obstructive pulmonary disease; Dyspnea; Muscarinic agents; Spirometry; Tobacco smoking

Indexed keywords

ARFORMOTEROL; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FORMOTEROL; GLUCOCORTICOID; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MUSCARINIC AGENT; OMALIZUMAB; ORCIPRENALINE; PIRBUTEROL; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; CHOLINERGIC RECEPTOR STIMULATING AGENT; LEUKOCYTE ELASTASE;

ADULT; ASTHMA; CASE MANAGEMENT; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; DISEASE SEVERITY; DRUG CHOICE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MALE; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PATIENT REFERRAL; REVIEW; SMOKING; SPIROMETRY; VITAL CAPACITY; ARTICLE; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; DIFFERENTIAL DIAGNOSIS; FOLLOW UP; METHODOLOGY; MIDDLE AGED; NEUTROPHIL; PATHOLOGY; PHYSIOLOGY; RISK FACTOR; SPUTUM;

ADRENERGIC BETA-AGONISTS; ASTHMA; CHOLINERGIC AGENTS; DIAGNOSIS, DIFFERENTIAL; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; LEUKOCYTE ELASTASE; MALE; MIDDLE AGED; NEUTROPHILS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SMOKING; SPIROMETRY; SPUTUM; TOMOGRAPHY, X-RAY COMPUTED;

EID: 67549093417     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.05.2009     Document Type: Review

References (50)

1. Orie NGM, Sluiter HJ, eds. Bronchitis. Assen, The Netherlands: Royal van Gorcum; 1961:43-59.
2. Silva GE, Sherrill DL, Guerra S, Barbee RA. Asthma as a risk factor for COPD in a longitudinal study. Chest. 2004;126(1):59-65. (Pubitemid 38943118)
3. National Heart, Lung, and Blood Institute. Diseases and Condition Index. Who is at risk for asthma? www.nhlbi.nih.gov/health/dci/Diseases/Asthma/Asthma- WhoIsAtRisk.html. Accessed June 15, 2008.
4. Enright PL, McClelland RL, Newman AB, Gottlieb DJ, Lebowitz MD. Underdiagnosis and undertreatment of asthma in the elderly. Chest. 1999;116(3):603-613.
5. Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. Eur Respir J. 2004;24(5):822-833.
6. Meyers DA, Postma DS, Stine OC, et al. Genome screen for asthma and bronchial hyperresponsiveness: interactions with passive smoke exposure. J Allergy Clin Immunol. 2005;115(6):1169-1175. (Pubitemid 40824585)
7. Colilla S, Nicolae D, Pluzhnikov A, et al; Collaborative Study for the Genetics of Asthma. Evidence for gene-environment interactions in a linkage study of asthma and smoking exposure. J Allergy Clin Immunol. 2003;111(4):840-846.
8. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2008. www.goldcopd.com. Accessed April 13, 2009.
9. Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989;299(6710):1259-1260. (Pubitemid 19280051)
10. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2000;160(11):1683-1689.
11. Weiss W. Cigarette smoking and lung cancer trends. Chest. 1997;111(5):1414-1416.
12. Silverman EK. Genetic epidemiology of COPD. Chest. 2002;121(suppl 3):1S-6S. (Pubitemid 34248307)
13. Hogarth DK, Rachelefsky G. Screening and familial testing of patients alpha-1 antitrypsin deficiency. Chest. 2008;133(4):981-988.
14. van der Pouw, Kraan TC, Küçükaycan M, et al. Chronic obstructive pulmonary disease is associated with the - 1055 IL-13 promoter polymorphism. Genes Immun. 2002;3(7):436-439. (Pubitemid 41656545)
15. Postma DS, Bleecker ER, Amelung PJ, et al. Genetic susceptibility to asthma - bronchial hyperresponsiveness coinherited with a major gene for atopy. N Engl J Med. 1995;333(14):894-900.
16. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2008. www.ginasthma.com. Accessed April 13, 2009.
17. Spencer LT, Paone G, Krein PM, et al. Role of human neutrophil peptides in lung inflammation associated with a1-antitrypsin deficiency. Am J Physiol Lung Cell Mol Physiol. 2004;286(3):L514-L520. (Pubitemid 38233622)
18. Hogg JC, Chu F, Utokaparch S, et al. The nature of small airways obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645-2653. (Pubitemid 38787999)
19. Ito K, Ito M, Elliot WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005;352(19):1967-1976. (Pubitemid 40638367)
20. Adcock IM, Ito K, Barnes PJ. Histone deacetylation: an important mechanism in inflammatory lung disease. COPD. 2005;2(4):445-455. (Pubitemid 43879443)
21. Marwick JA, Ito K, Adcock IM, Kirkham PA. Oxidative stress and steroid resistance in asthma and COPD: pharmacological manipulation of HDAC-2 as a therapeutic strategy. Expert Opin Ther Targets. 2007;11(6):745-755. (Pubitemid 46901395)
22. Molfino M. Genetics of COPD. Chest. 2004;125(5):1929-1940. (Pubitemid 38648430)
23. Gelb AF, Zamel N, Krishnan A. Physiologic similarities and differences between asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2008;14(1):24-30. (Pubitemid 350191035)
24. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet. 2006;368(9537):804-813. (Pubitemid 44279058)
25. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapcutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med. 2003;168(11):1308-1311. (Pubitemid 37487324)
26. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003;58(8):659-664. (Pubitemid 36976273)
27. Kesten S, Rebuck AS. Is the short-term response to inhaled beta-adrenergic agonist sensitive or specific for distinguishing between asthma and COPD? Chest. 1994;105(4):1042-1045.
28. Price DB, Tinkelman DG, Halbert RJ, et al. Symptom-based questionnaire for identifying COPD in smokers. Respiration. 2006;73(3):285-295. (Pubitemid 43739190)
29. Tinkelman DG, Price DB, Nordyke RJ, et al. Symptom-based questionnaire for differentiating COPD from asthma. Respiration. 2006;73(3):296-305. (Pubitemid 43725786)
30. Jiva TM, Israel RH, Poe RH. Tropical pulmonary eosinophilia masquerading as acute bronchial asthma. Respiration. 1996;63(1):55-58. (Pubitemid 26039589)
31. Vijayan VK. Tropical pulmonary eosinophilia: pathogenesis, diagnosis and management. Curr Opin Pulm Med. 2007;13(5):428-433. (Pubitemid 47472306)
32. US Preventive Services Task Force. Screening for chronic obstructive pulmonary disease using spirometry: US Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2008;148(7):529-534. (Pubitemid 351665423)
33. Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jiminez P. Safety and tolerability of omalizumab [published online ahead of print March 17, 2009]. Clin Exp Allergy.
34. Calverley PM, Anderson JA, Celli B, et al; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2008;356(8):775-789.
35. Tashkin DP, Celli B, Senn S, et al; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-1554.
36. Macie, C, Wooldrage, K, Manfreda, J, Anthonisen NR. Inhaled corticosteroids and mortality in COPD. Chest. 2006;130(3):640-646.
37. Sin DD, Tu JV. Inhaled corticosteroids and risk of mortality and readmission in elder patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(4):580-584. (Pubitemid 32801660)
38. Sin DD, Man SF. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Eur Respir J. 2003;21(2):260-266.
39. Soriano JB, Kiri VA, Pride NB, Vestbo J. Inhaled corticosteroids with/without long acting agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med. 2003;2(1):67-74. (Pubitemid 37062718)
40. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J. 2002;20(4):819-825. (Pubitemid 35175115)
41. Sin DD, Man SFP, Tu JV. Inhaled glucocorticoids in COPD: immortal time bias. Am J Respir Crit Care Med. 2003;168(1):126-127.
42. Sin DD, Paul Man SF. Cooling the fire within: inhaled corticosteroids and cardiovascular mortality in COPD. Chest. 2006;130(3):629-631. (Pubitemid 44423584)
43. Kempainen RR, Savik K, Whelan TP, Dunitz JM, Herrington CS, Billings JL. High prevalence of proximal and distal gastroesophageal reflux disease in advanced COPD. Chest. 2007;131(6):1666-1671. (Pubitemid 46981618)
44. Niklasson A, Strid H, Simrén M, Engström CP, Björnsson E. Prevalence of gastrointestinal symptoms in patients with chronic obstructive pulmonary disease. Eur J Gastroenterol Hepatol. 2008;20(4):335-341.
45. Jiang SP, Huang LW. Role of gastroesophageal reflux disease in asthmatic patients. Eur Rev Med Pharmacol Sci. 2005;9(3):151-160. (Pubitemid 40975764)
46. Dixon AE. Rhinosinusitis and asthma: the missing link. Curr Opin Pulm Med. 2009;15(1):19-24.
47. Kim JS, Rubin BK. Nasal and sinus inflammation in chronic obstructive pulmonary disease. COPD. 2007;4(2):163-166. (Pubitemid 47164869)
48. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932-946.
49. O'Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. Can Respir J. 2008;15(suppl A):1A-8A. (Pubitemid 351566057)
50. British Thoracic Society Standards of Care Committee. BTS statement on criteria for specialist referral, admission, discharge and follow-up for adults with respiratory disease. Thorax. 2008;63(suppl 1):i1-i16.